Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.32 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GLB1 | P16278 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27326201 | 1.00 | GBA1 (0.36) | GBA1PYGLGBA2GAAGLB1 | |
| SCHEMBL2904835 | 1.00 | GBA1 (0.36) | GBA1PYGLGBA2GAAGLB1 | |
| Hydrochloric Acid SCHEMBL2905226 | 0.98 | GBA1 (0.35) | GBA1PYGLGBA2GAAGLB1 | |
| SCHEMBL26729416 | 0.84 | GBA1 (0.36) | GBA1PYGLGBA2GAAGLB1 | |
| SCHEMBL2904780 | 0.84 | GBA1 (0.36) | GBA1PYGLGBA2GAAGLB1 | |
| Tert-Butyl Formate SCHEMBL28026809 | 0.83 | TDP1 (0.36) | — | |
| Hydrochloric Acid SCHEMBL2923844 | 0.82 | GBA1 (0.35) | GBA1PYGLGBA2GAAGLB1 | |
| Hydrochloric Acid SCHEMBL2923841 | 0.82 | GBA1 (0.35) | GBA1PYGLGBA2GAAGLB1 | |
| Hydrochloric Acid SCHEMBL2923847 | 0.82 | GBA1 (0.35) | GBA1PYGLGBA2GAAGLB1 | |
| SCHEMBL3182445 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604964-B2 | Dihydropyrazole GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2925749-B1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160297797-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-13 | — | — | US | disclosed |
| EP-2925749-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2015-10-07 | — | — | EP | disclosed |
| CN-104918935-A | Dihydropyrazole gpr40 modulators | BRISTOL MYERS SQUIBB CO | 2015-09-16 | — | — | CN | disclosed |
| WO-2014078611-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-22 | — | — | WO | disclosed |
| CN-103224464-A | Cyclohexene derivative or its pharmaceutically acceptable salt and application thereof | ZHANG JIANCUN | 2013-07-31 | — | — | CN | disclosed |
| EP-2010506-B1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297797-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | GPR55, GPR65, GPR35 | GBA1 3580/4885PYGL 4475/4885GBA2 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.